<DOC>
	<DOC>NCT02445794</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of RT001 in patients with Friedreich's ataxia.</brief_summary>
	<brief_title>A First in Human Study of RT001 in Patients With Friedreich's Ataxia</brief_title>
	<detailed_description>Study RT001-002 is a randomized, double-blind, controlled, ascending dose study to evaluate the safety, tolerability, pharmacokinetic, disease state, and exploratory endpoints in patients with Friedreich's ataxia after oral administration. The study includes 2 dose levels of RT001.</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<criteria>1. Male or female 18 to 50 years of age 2. Medical history consistent with the symptoms of FRDA at ≤ 25 years of age 3. Homozygous for GAA repeat expansions in the Frataxin gene in the affected range for FRDA 4. FARSNeurological score of 2090 points 5. Ambulatory (with or without assistive device) and capable of performing assessments/evaluations 6. Body Mass Index ≤ 29.9 kg/m2 7. Agrees to dietary restrictions and agrees to receive calls from a dietary coach 8. Signed the informed consent form prior to entry into the study 9. Agrees to spend the required number of overnight clinic days 10. Able to provide the necessary repeated blood samples 1. Received treatment with other experimental therapies within the last 30 days prior to the first dose 2. Known point mutation in the FXN gene 3. History of malignancies (other than basal cell carcinomas) 4. Impaired renal function at screening 5. Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values &gt; 2 x upper limit of normal (ULN) at screening 6. Known hepatitis B surface antigen (HBsAg)positive, or known or suspected active hepatitis C infection, or is known to be human immunodeficiency virus (HIV) positive 7. Female who is breastfeeding or has a positive pregnancy test 8. Male participant or female participant of child bearing potential, who is sexually active and unwilling/unable to use a medically acceptable and effective double barrier birth control method throughout the study 9. Unwilling or unable to comply with the requirements of the protocol 10. Clinically significant cardiac abnormalities at screening that, in the opinion of the Investigator, would make the patient unsuitable for enrollment 11. Diabetes mellitus (Type 1 or 2) 12. Suicidal ideation as determined by the ColumbiaSuicide Severity Rating Scale 13. History, within the last 2 years, of alcohol abuse, significant mental illness, or physical opioid dependence 14. Cannot adhere to the dietary guidance required to be followed by the protocol 15. Cannot take the medication due to impairment in swallowing capsules</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>